IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023
| Statement of transactions in own shares from November 06 to November 10, 2023 | BNP PARIBAS | |||||||||
| Aggregated presentation by day and by market | ||||||||||
| Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) | ||||
| IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 266 | 110.07 | AQEU | ||||
| IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 710 | 110.64 | CEUX | ||||
| IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 213 | 111.09 | TQEX | ||||
| IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 2,630 | 110.49 | XPAR | ||||
| * Two-digit rounding after the decimal | TOTAL | 3,819 | 110.52 | |||||||
Attachment
14 October 2024
1 mins read
Excellence in action: Ipsen is first pharma company to receive two Gold Shingo Prizes
29 June 2022
1 mins read
Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission
01 June 2021
1 mins read
Ipsen announces the launch of an Employee Shareholding Plan